ArticleBMC gastroenterology2026
Epidemiology of diagnosed inflammatory bowel disease in Taiwan population from 2011 to 2021: a population-based study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) has shown a steadily rising prevalence in Asian populations over recent decades, coinciding with rapid industrialization, Westernized dietary habits, and lifestyle changes. This study aimed to report the annual trends and sociodemographic-specific rates of the prevalence and incidence of diagnosed IBD in Taiwan from 2011 to 2021.
methodsA population-based study of all residents enrolled in the National Health Insurance (NHI) program, the Catastrophic Illness Patient Database, was conducted to identify patients diagnosed with IBD. The annual prevalence and incidence of diagnosed IBD were identified using International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9-CM and ICD-10-CM) diagnostic codes, stratified by age, sex, insurance premium, and degree of urbanization. Logistic regression analyses were performed to estimate odds ratios for associated risk factors; while Joinpoint regression analyses were used to assess temporal trends in age-standardized annual prevalence and incidence from 2011 to 2021.
resultsThe age-standardized annual prevalence of IBD more than doubled from 9.56 per 100,000 persons in 2011 to 19.54 per 100,000 in 2021 (annual percent change [APC]: 7.35%), while incidence rates rose from 0.89 to 2.46 per 100,000 persons over the same period (APC: 11.04%). Males consistently showed higher prevalence and incidence rates than females throughout the study period. Prevalence was highest among individuals aged 50-60 years, those with high income levels, and residents of highly urbanized areas, whereas incidence peaked in the 40-50-year age group and was also elevated among individuals with high income.
conclusionsNationwide NHI data showed a substantial increase in IBD prevalence and incidence in Taiwan from 2011 to 2021, with a disproportionately increased burden among men, middle-aged individuals, high-income groups, and residents of highly urbanized areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.